Integer Holdings (ITGR)
(Delayed Data from NYSE)
$126.17 USD
+1.92 (1.55%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $126.25 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$126.17 USD
+1.92 (1.55%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $126.25 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
QuidelOrtho's (QDEL) Latest FDA Nod to Boost Diagnostic Testing
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's latest approval is likely to improve clinical care, provide cost savings and deliver sample-to-result molecular testing across all laboratory settings.
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Veeva Systems (VEEV) Vault Quality Offerings Adopted by Recipharm
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid Recipharm in boosting its operational efficiencies.
3 Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
by Zacks Equity Research
The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
by Zacks Equity Research
Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
Masimo's (MASI) Stork Baby Monitoring System Approved by FDA
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
Why Integer (ITGR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene (CNC) Ties Up to Aid Its Marketplace Members in Chicago
by Zacks Equity Research
Centene's (CNC) product - Ambetter of Illinois - along with RUSH aim to provide improved access to quality healthcare services for CNC's members in Chicago, and thereby grow its Marketplace business.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Masimo's (MASI) ORi Favored by Study for PaO2 Information
by Zacks Equity Research
Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
McKesson (MCK) Announces Availability of FDA-Approved Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.
BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod
by Zacks Equity Research
BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.